{"id": 2, "relation": 0, "prompt": "<e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 82, "relation": 1, "prompt": "Use of Anticoagulants and Antiplatelet Agents -- <e1> Streptase </e1> , Streptokinase, alone or in combination with <e2> antiplatelet agents </e2> and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " true"}
{"id": 16, "relation": 0, "prompt": "<e1> Cyclosporine </e1> : When studied in stable renal transplant patients, <e2> cyclosporine </e2> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.\n\n###\n\n", "completion": " false"}
{"id": 85, "relation": 1, "prompt": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, <e1> Streptokinase </e1> , alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.\n\n###\n\n", "completion": " true"}
{"id": 17, "relation": 0, "prompt": "<e1> Cyclosporine </e1> : When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> Myfortic </e2> .\n\n###\n\n", "completion": " false"}
{"id": 107, "relation": 1, "prompt": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e1> erythromycin </e1> , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " true"}
{"id": 20, "relation": 0, "prompt": "<e1> Acyclovir </e1> /Ganciclovir: may be taken with <e2> Myfortic </e2> ;\n\n###\n\n", "completion": " false"}
{"id": 126, "relation": 1, "prompt": "Interaction with Guanethidine: Although <e1> minoxidil </e1> does not itself cause orthostatic hypotension, its administration to patients already receiving <e2> guanethidine </e2> can result in profound orthostatic effects.\n\n###\n\n", "completion": " true"}
{"id": 22, "relation": 0, "prompt": "Both <e1> acyclovir </e1> / <e2> ganciclovir </e2> and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.\n\n###\n\n", "completion": " false"}
{"id": 150, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, <e2> antiarrhythmic agents of class I </e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 31, "relation": 0, "prompt": "Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that <e2> azathioprine </e2> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 153, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 33, "relation": 0, "prompt": "Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 154, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 44, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1> Myfortic </e1> not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 256, "relation": 1, "prompt": "<e1> Anticholinergic agents </e1> may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of <e2> digoxin </e2> ;\n\n###\n\n", "completion": " true"}
{"id": 45, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e1> azathioprine </e1> or <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 268, "relation": 1, "prompt": "The concurrent use of <e1> streptozocin </e1> and <e2> phenytoin </e2> has been reported in one case to result in reduced streptozocin cytotoxicity.\n\n###\n\n", "completion": " true"}
{"id": 48, "relation": 0, "prompt": "Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e1> MPA </e1> exposure when coadministered with <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " false"}
{"id": 669, "relation": 1, "prompt": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e1> dipyridamole </e1> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 54, "relation": 0, "prompt": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e1> activated charcoal </e1> , because of the potential to reduce the efficacy of <e2> Myfortic </e2> .\n\n###\n\n", "completion": " false"}
{"id": 688, "relation": 1, "prompt": "<e1> Zidovudine </e1> competitively inhibits the intracellular phosphorylation of <e2> stavudine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 65, "relation": 0, "prompt": "<e1> Tetracycline </e1> , a bacteriostatic <e2> antibiotic </e2> , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.\n\n###\n\n", "completion": " false"}
{"id": 690, "relation": 1, "prompt": "In vitro data indicate that the phosphorylation of <e1> stavudine </e1> is also inhibited at relevant concentrations by <e2> doxorubicin </e2> and ribavirin.\n\n###\n\n", "completion": " true"}
{"id": 70, "relation": 0, "prompt": "Drugs which may potentiate the myeloproliferative effects of Leukine, such as <e1> lithium </e1> and <e2> corticosteroids </e2> , should be used with caution.\n\n###\n\n", "completion": " false"}
{"id": 699, "relation": 1, "prompt": "In addition to bleeding associated with <e1> heparin </e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 76, "relation": 0, "prompt": "Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 706, "relation": 1, "prompt": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1> aspirin </e1> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 77, "relation": 0, "prompt": "Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- <e2> Streptase </e2> , Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 920, "relation": 1, "prompt": "Reduced absorption of <e1> folic acid </e1> and digoxin have been reported when those agents were administered concomitantly with <e2> sulfasalazine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 78, "relation": 0, "prompt": "Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- Streptase, <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 921, "relation": 1, "prompt": "Reduced absorption of folic acid and <e1> digoxin </e1> have been reported when those agents were administered concomitantly with <e2> sulfasalazine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 88, "relation": 0, "prompt": "Anticoagulation and <e1> Antiplatelets </e1> After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of <e2> aspirin </e2> has been shown to reduce the incidence of reinfarction and stroke.\n\n###\n\n", "completion": " false"}
{"id": 1026, "relation": 1, "prompt": "Use of potassium-sparing diuretics (spironolactone, triamterene, <e1> amiloride </e1> ) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.\n\n###\n\n", "completion": " true"}
{"id": 97, "relation": 0, "prompt": "No dosage adjustment of <e1> digoxin </e1> or <e2> JANUVIA </e2> is recommended.\n\n###\n\n", "completion": " false"}
{"id": 1543, "relation": 1, "prompt": "Coadministration of <e1> TRITEC </e1> with <e2> clarithromycin </e2> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).\n\n###\n\n", "completion": " true"}
{"id": 98, "relation": 0, "prompt": "Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e2> ketoconazole </e2> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1568, "relation": 1, "prompt": "<e1> Ethanol </e1> decreases the elimination of <e2> abacavir </e2> causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.\n\n###\n\n", "completion": " true"}
{"id": 111, "relation": 0, "prompt": "John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, phenobarbital, <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1574, "relation": 1, "prompt": "In a study of 11 HIV-infected patients receiving <e1> methadone </e1> -maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e2> ZIAGEN </e2> twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).\n\n###\n\n", "completion": " true"}
{"id": 113, "relation": 0, "prompt": "John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " false"}
{"id": 1833, "relation": 1, "prompt": "Cholestyramine: Concomitant <e1> cholestyramine </e1> administration decreased the mean AUC of total <e2> ezetimibe </e2> approximately 55%.\n\n###\n\n", "completion": " true"}
{"id": 114, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , <e2> phenobarbital </e2> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 1834, "relation": 1, "prompt": "The incremental LDL-C reduction due to adding <e1> ezetimibe </e1> to <e2> cholestyramine </e2> may be reduced by this interaction.\n\n###\n\n", "completion": " true"}
{"id": 125, "relation": 0, "prompt": "Interaction with <e1> Guanethidine </e1> : Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving <e2> guanethidine </e2> can result in profound orthostatic effects.\n\n###\n\n", "completion": " false"}
{"id": 1886, "relation": 1, "prompt": "The action of <e1> Mecamylamine </e1> may be potentiated by anesthesia, other <e2> antihypertensive drugs </e2> and alcohol.\n\n###\n\n", "completion": " true"}
{"id": 130, "relation": 0, "prompt": "<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1896, "relation": 1, "prompt": "<e1> Salicylates </e1> may enhance the hypoglycemic effect of oral <e2> antidiabetic drugs </e2> of the sulfonylurea class.\n\n###\n\n", "completion": " true"}
{"id": 135, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1898, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, <e2> thiopental </e2> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 138, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1899, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 139, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1902, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 142, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1959, "relation": 1, "prompt": "<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .\n\n###\n\n", "completion": " true"}
{"id": 148, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e1> Killed virus vaccines </e1> : may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1990, "relation": 1, "prompt": "The use of <e1> AGGRASTAT </e1> , in combination with <e2> heparin </e2> and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see\n\n###\n\n", "completion": " true"}
{"id": 166, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2011, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 178, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2028, "relation": 1, "prompt": "Some <e1> diuretics </e1> can enhance <e2> aminoglycoside </e2> toxicity by altering antibiotic concentrations in serum and tissue.\n\n###\n\n", "completion": " true"}
{"id": 179, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2045, "relation": 1, "prompt": "<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, <e2> alcohol </e2> , etc.)\n\n###\n\n", "completion": " true"}
{"id": 180, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2177, "relation": 1, "prompt": "In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e1> fluconazole </e1> concurrently with <e2> warfarin </e2> .\n\n###\n\n", "completion": " true"}
{"id": 185, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2193, "relation": 1, "prompt": "Rifampin: <e1> Rifampin </e1> enhances the metabolism of concurrently administered <e2> DIFLUCAN </e2> .\n\n###\n\n", "completion": " true"}
{"id": 187, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2206, "relation": 1, "prompt": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e1> DIFLUCAN </e1> taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2> terfenadine </e2> when taken concomitantly.\n\n###\n\n", "completion": " true"}
{"id": 188, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2212, "relation": 1, "prompt": "A controlled study found that concomitant <e1> fluconazole </e1> 200 mg once daily and <e2> cisapride </e2> 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.\n\n###\n\n", "completion": " true"}
{"id": 190, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2280, "relation": 1, "prompt": "However, increased prothrombin time and bleeding have been reported in patients on concomitant <e1> TOLECTIN </e1> and <e2> warfarin </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 191, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2290, "relation": 1, "prompt": "<e1> TOLECTIN </e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of <e2> methotrexate </e2> in an animal model, possibly enhancing the toxicity of methotrexate.\n\n###\n\n", "completion": " true"}
{"id": 197, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2321, "relation": 1, "prompt": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1> phenytoin </e1> , carbamazepine, and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.\n\n###\n\n", "completion": " true"}
{"id": 199, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2376, "relation": 1, "prompt": "Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and <e2> fluconazole </e2> .\n\n###\n\n", "completion": " true"}
{"id": 209, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2398, "relation": 1, "prompt": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, <e1> ketoconazole </e1> , miconazole) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.\n\n###\n\n", "completion": " true"}
{"id": 213, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2612, "relation": 1, "prompt": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.\n\n###\n\n", "completion": " true"}
